The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

A post-hoc analysis showed more pronounced effects among patients on risperidone compared to those on other antipsychotics, ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

ArriVent BioPharma, Inc.’s AVBP share price has surged by 6.01%, which has investors questioning if this is right time to ...

Atossa Therapeutics, Inc.’s ATOS share price has surged by 5.39%, which has investors questioning if this is right time to ...

There are four emerging powerhouses in China biotech: Henlius, BeiGene, Innovent and ZaiLab. All were founded in the 2010s, ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Shares of Aclaris Therapeutics were trading higher after the company said regulators had cleared its new drug application for a trial of ATI-052, its potential treatment for immuno-inflammatory ...

AEON Biopharma named Rob Bancroft as its new chief executive. The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings ...

In summary, income-focused investors may find Pfizer stock an attractive option for making a steady income of $100 per month ...